More exciting news about our licensed PDT agent as it is granted a second patent due to the success of the first clinical trial for non-muscle invasive bladder cancer.
Our work has been featured by the Nova Scotia Research and Innovation Trust.
McFarland Labs to use new equipment to capture the inner workings of drugs in cells in fight against cancer.
Many things have happened with our licenced PDT agent over the past few months. Continue on to learn of the advances our drug is making.
Our licensed compound TLD-1433 has been identified as the lead photodynamic compound for human clinical trials!
President and CEO of Theralase, Roger Dumoulin-White, discusses the Company's progress on its ground breaking anti-cancer research on CBC’s The Lang and O’Leary Exchange.
The latest research on Photo Dynamic Compound (PDC) technology from Theralase Technologies, proven effective in the destruction of bacteria and cancer, was peer reviewed and invited to be published in Coordination Chemistry Reviews as the company prepares for human clinical trials.
Theralase Technologies Inc. announced today that its latest research on Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, was peer reviewed and invited to be published in the prestigious US Elsevier publication, Coordination Chemistry Reviews.
Theralase Technologies Inc. announced today that it has advanced its anti-cancer technology platform through an executed research agreement with Acadia University.